keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast cancer therapy

keyword
https://www.readbyqxmd.com/read/28932627/addition-of-anti-estrogen-therapy-to-anti-her2-dendritic-cell-vaccination-improves-regional-nodal-immune-response-and-pathologic-complete-response-rate-in-patients-with-er-pos-her2-pos-early-breast-cancer
#1
Lea Lowenfeld, Salman Zaheer, Crystal Oechsle, Megan Fracol, Jashodeep Datta, Shuwen Xu, Elizabeth Fitzpatrick, Robert E Roses, Carla S Fisher, Elizabeth S McDonald, Paul J Zhang, Angela DeMichele, Rosemarie Mick, Gary K Koski, Brian J Czerniecki
HER2-directed therapies are less effective in patients with ER(pos) compared to ER(neg) breast cancer, possibly reflecting bidirectional activation between HER2 and estrogen signaling pathways. We investigated dual blockade using anti-HER2 vaccination and anti-estrogen therapy in HER2(pos)/ER(pos) early breast cancer patients. In pre-clinical studies of HER2(pos) breast cancer cell lines, ER(pos) cells were partially resistant to CD4(+) Th1 cytokine-induced metabolic suppression compared with ER(neg) cells...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28927763/imaging-considerations-and-interprofessional-opportunities-in-the-care-of-breast-cancer-patients-in-the-neoadjuvant-setting
#2
REVIEW
Anna G Sorace, Sara Harvey, Anum Syed, Thomas E Yankeelov
OBJECTIVE: To discuss standard-of-care and emerging imaging techniques employed for screening and detection, diagnosis and staging, monitoring response to therapy, and guiding cancer treatments. DATA SOURCES: Published journal articles indexed in the National Library of Medicine database and relevant websites. CONCLUSION: Imaging plays a fundamental role in the care of cancer patients and specifically, breast cancer patients in the neoadjuvant setting, providing an excellent opportunity for interprofessional collaboration between oncologists, researchers, radiologists, and oncology nurses...
September 15, 2017: Seminars in Oncology Nursing
https://www.readbyqxmd.com/read/28923573/neoadjuvant-buparlisib-plus-trastuzumab-and-paclitaxel-for-women-with-her2-primary-breast-cancer-a-randomised-double-blind-placebo-controlled-phase-ii-trial-neophoebe
#3
Sibylle Loibl, Lorena de la Pena, Valentina Nekljudova, Dimitrios Zardavas, Stefan Michiels, Carsten Denkert, Mahdi Rezai, Begoña Bermejo, Michael Untch, Soo Chin Lee, Sabine Turri, Patrick Urban, Sherko Kümmel, Guenther Steger, Andrea Gombos, Michael Lux, Martine J Piccart, Gunter Von Minckwitz, José Baselga, Sherene Loi
AIM: The Neoadjuvant PI3K inhibition in HER2 OverExpressing Breast cancEr (NeoPHOEBE) trial evaluated the efficacy and safety of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus trastuzumab and paclitaxel as neoadjuvant treatment for human epidermal growth factor receptor-2 positive (HER2+) breast cancer. METHODS: NeoPHOEBE was a neoadjuvant, phase II, randomised, double-blind study. Women with HER2+ breast cancer were randomised within two independent cohorts by PIK3CA mutation status and, in each cohort stratified by oestrogen receptor (ER) status to receive buparlisib or placebo plus trastuzumab (first 6 weeks) followed by buparlisib or placebo with trastuzumab and paclitaxel...
September 15, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28922685/neoadjuvant-systemic-therapy-for-breast-cancer-the-westmead-experience
#4
Annelise M Cocco, David Messer, Alexander Brown, Nina Sriram, Jenny Gilchrist, Loma Al-Mansouri, Richard Kefford, Farid Meybodi, James French, Jeremy Hsu, Elisabeth Elder
BACKGROUND: Neoadjuvant systemic therapy (NAST) can be used to treat breast cancer. Pathologic complete response (pCR) is a surrogate marker for improved survival. This study examined response in the breast and axilla to NAST and identified features associated with pCR. METHODS: Patients undergoing NAST and surgery between January 2012 and June 2016 by surgeons at Westmead Breast Cancer Institute were identified. Patients with inflammatory or metastatic disease were excluded...
September 18, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28915617/predictive-factors-of-pathologic-complete-response-in-her2-positive-and-axillary-lymph-node-positive-breast-cancer-after-neoadjuvant-paclitaxel-carboplatin-plus-with-trastuzumab
#5
Jinhua Ding, Yinlong Yang, Li Jiang, Weizhu Wu, Zhiming Shao
OBJECTIVE: This study was performed to investigate the proportion as well as the predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab (PCH). RESULTS: The pCR rate in the breast, axilla and both was 44.3% (39/88), 47.7% (42/88) and 34.1% (30/88), respectively. Patients with and without pCR were similar in term of age, BMI, menstrual status, family history, treatment cycles and tumor characteristics (laterality and size of tumor)...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28911063/stromal-lymphocyte-infiltration-after-neoadjuvant-chemotherapy-is-associated-with-aggressive-residual-disease-and-lower-disease-free-survival-in-her2-positive-breast-cancer
#6
A-S Hamy, J-Y Pierga, A Sabaila, E Laas, H Bonsang-Kitzis, C Laurent, A Vincent-Salomon, P Cottu, F Lerebours, R Rouzier, M Lae, F Reyal
Background: The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade. High TILs levels have been associated with pathological response rate in the neoadjuvant setting and with better outcomes in the adjuvant setting. However, little attention has been paid to changes in TILs and residual TIL levels after neoadjuvant chemotherapy (NAC). We investigated TIL levels before, after chemotherapy, and their dynamics during treatment; and we assessed the correlation of these levels with response to NAC and prognosis...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28905250/tumour-infiltrating-lymphocytes-tils-related-genomic-signature-predicts-chemotherapy-response-in-breast-cancer
#7
Mariko Kochi, Takayuki Iwamoto, Naoki Niikura, Giampaolo Bianchini, Shinobu Masuda, Taeko Mizoo, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Yutaka Tokuda, Hiroyoshi Doihara, Junji Matsuoka, Toshiyoshi Fujiwara
PURPOSE: The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several breast cancer subtypes. METHODS: We retrospectively evaluated haematoxylin eosin (HE)-TILs levels and gene expression profiling data from 40 patients with primary breast cancer and extracted the 22 overexpressed genes in cases with high TILs scores as the TILs-GS...
September 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28893303/contrast-enhanced-spectral-mammography-in-neoadjuvant-chemotherapy-monitoring-a-comparison-with-breast-magnetic-resonance-imaging
#8
Valentina Iotti, Sara Ravaioli, Rita Vacondio, Chiara Coriani, Sabrina Caffarri, Roberto Sghedoni, Andrea Nitrosi, Moira Ragazzi, Elisa Gasparini, Cristina Masini, Giancarlo Bisagni, Giuseppe Falco, Guglielmo Ferrari, Luca Braglia, Alberto Del Prato, Ivana Malavolti, Vladimiro Ginocchi, Pierpaolo Pattacini
BACKGROUND: Neoadjuvant-chemotherapy (NAC) is considered the standard treatment for locally advanced breast carcinomas. Accurate assessment of disease response is fundamental to increase the chances of successful breast-conserving surgery and to avoid local recurrence. The purpose of this study was to compare contrast-enhanced spectral mammography (CESM) and contrast-enhanced-MRI (MRI) in the evaluation of tumor response to NAC. METHODS: This prospective study was approved by the institutional review board and written informed consent was obtained...
September 11, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28890185/stromal-clusterin-expression-predicts-therapeutic-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#9
Yihong Wang, Alexander S Brodsky, Jinjun Xiong, Mary L Lopresti, Dongfang Yang, Murray B Resnick
BACKGROUND: Expression of clusterin correlates with tumor progression and therapeutic response in several human malignancies, including breast cancer. However, its predictive value in the neoadjuvant setting in breast cancer remains unexplored. The objective of this explorative study was to determine whether clusterin expression in breast cancer correlated with clinical pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS: We determined the clusterin expression pattern in 72 triple negative breast cancers (TNBC) treated with NAC before surgery...
August 19, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28883001/kdm4-inhibition-targets-breast-cancer-stem-like-cells
#10
Eric Metzger, Stella S Stepputtis, Juliane Strietz, Bogdan-Tiberius Preca, Sylvia Urban, Dominica Willmann, Anita Allen, Fides Zenk, Nicola Iovino, Peter Bronsert, Amelie Proske, Marie Follo, Melanie Boerries, Elmar Stickeler, Jiangchun Xu, Michael B Wallace, Jeffrey A Stafford, Toufike Kanouni, Jochen Maurer, Roland Schüle
Traditional treatments for breast cancer fail to address therapy-resistant cancer stem-like cells that have been characterized by changes in epigenetic regulators such as the lysine demethylase KDM4. Here we describe an orally available, selective and potent KDM4 inhibitor (QC6352) with unique preclinical characteristics. To assess the anti-tumor properties of QC6352, we established a method to isolate and propagate breast cancer stem-like cells (BCSC) from individual triple-negative tumors resected from patients after neoadjuvant chemotherapy...
September 7, 2017: Cancer Research
https://www.readbyqxmd.com/read/28878653/correlation-between-tumor-infiltrating-lymphocytes-and-pathological-response-in-locally-advanced-breast-cancer-patients-who-received-neoadjuvant-chemotherapy-in-h-adam-malik-general-hospital
#11
Kamal Basri Siregar, Jamaluddin Pane, Rikson Siburian
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value, particularly in triple-negative and human epidermal growth factor receptor-2-positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy, and there is a strong correlation with pathologically complete response...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28876590/surgery-post-neoadjuvant-therapy-for-breast-cancer-an-analysis-of-82-patients-treated-at-a-specialist-unit-in-johannesburg
#12
L Van Schalkwyk, C Benn, K Bergstrom
INTRODUCTION: Neoadjuvant therapy in the breast cancer setting not only provides an indication of response to systemic therapy, but also results in tumour downsizing/downstaging, which facilitates breast conservation therapy (BCT). The aim of this retrospective analysis is to examine the surgical management of patients who have received neoadjuvant therapy for breast cancer at the Netcare Breast Care Centre (NCBC) in Johannesburg. METHOD: All breast cancer patients managed surgically at the NCBC after neoadjuvant chemotherapy/primary endocrine therapy were identified from a database of 431 breast cancer patients presenting to this facility from June 2015 to June 2016...
September 2017: South African Journal of Surgery. Suid-Afrikaanse Tydskrif Vir Chirurgie
https://www.readbyqxmd.com/read/28876589/reconstruction-in-locally-advance-breast-cancer-who-what-and-when
#13
L Van Schalkwyk, C Benn, K Bergstrom
BACKGROUND: Locally advanced breast cancer (LABC) is defined as the most advanced stage of non-metastatic breast cancer. While breast reconstruction is not contraindicated in this subset of patients, the decision-making process is influenced by several considerations, including recurrence risk and the need for and timing of adjuvant therapy such as radiotherapy. This retrospective analysis investigates the reconstructive procedures performed on women presenting with locally advanced breast cancer at the Netcare Breast Care Centre (NCBC) in Johannesburg...
September 2017: South African Journal of Surgery. Suid-Afrikaanse Tydskrif Vir Chirurgie
https://www.readbyqxmd.com/read/28875243/outcome-after-neoadjuvant-chemotherapy-in-estrogen-receptor-positive-and-progesterone-receptor-negative-breast-cancer-patients-a-pooled-analysis-of-individual-patient-data-from-ten-prospectively-randomized-controlled-neoadjuvant-trials
#14
Marion T van Mackelenbergh, Carsten Denkert, Valentina Nekljudova, Thomas Karn, Christian Schem, Frederik Marmé, Elmar Stickeler, Christian Jackisch, Claus Hanusch, Jens Huober, Peter A Fasching, Jens-Uwe Blohmer, Sherko Kümmel, Volkmar Müller, Andreas Schneeweiss, Michael Untch, Gunter von Minckwitz, Karsten E Weber, Sibylle Loibl
PURPOSE: The estrogen receptor (ER) is involved in control of progesterone receptor (PgR) expression and lack of PgR may be also a surrogate of altered growth factor signaling. The aim of this study was therefore to investigate PgR expression as predictive factor for response to neoadjuvant therapy and long-term outcome. METHODS: Five thousand and six hundred and thirteen patients with primary breast cancer and positive ER expression from ten German neoadjuvant trials of anthracycline and taxane-based chemotherapy were included...
September 5, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28874413/a-phase-ii-trial-of-neoadjuvant-mk2206-an-akt-inhibitor-with-anastrozole-in-clinical-stage-2-or-3-pik3ca-mutant-er%C3%A2-positive-and-her2-negative-breast-cancer
#15
Cynthia X Ma, Vera Suman, Matthew P Goetz, Donald W Northfelt, Mark E Burkard, Foluso Ademuyiwa, Michael J Naughton, Julie Margenthaler, Rebecca Aft, Richard J Gray, Amye J Tevaarwerk, Lee G Wilke, Tufia C Haddad, Timothy Moynihan, Charles Loprenzi, Tina Hieken, Erica K Barnell, Zachary L Skidmore, Yan-Yang Feng, Kilannin Krysiak, Jeremy Hoog, Zhanfang Guo, Leslie Nehring, Kari B Wisinski, Elaine R Mardis, Ian S Hagemann, Kiran Vij, Souzan Sanati, Hussam Al-Kateb, Obi L Griffith, Malachi Griffith, Austin Doyle, Charles Erlichman, Matthew J Ellis
PURPOSE: Hyper-activation of AKT is common and associated with endocrine resistance in estrogen receptor positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA mutant ER+ breast cancer under estrogen-deprived condition in preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding MK-2206 to anastrozole induces pathologic complete response (pCR) in PIK3CA mutant ER+ breast cancer. EXPERIMENTAL DESIGN: Potential eligible patients with clinical stage II/III ER+/HER2- breast cancer were pre-registered and received anastrozole (goserelin if premenopausal) for 28 days in cycle 0 pending tumor PIK3CA sequencing...
September 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28872469/extending-indication-of-cyclin-dependent-kinase-4-6-inhibitors-in-the-adjuvant-and-neoadjuvant-setting
#16
Carmen Criscitiello, Giulia Viale, Giuseppe Curigliano
PURPOSE OF REVIEW: A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer. The success of these drugs in the metastatic setting has pushed the evaluation of these agents in early-stage disease. The use of CDK 4/6 inhibitors as neoadjuvant and adjuvant therapy is a hot topic and several studies are underway. RECENT FINDINGS: Ongoing studies are exploring the addition of CDK 4/6 inhibitors to endocrine therapy in early breast cancer...
September 1, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28870785/concurrent-neoadjuvant-chemotherapy-and-radiation-therapy-in-locally-advanced-breast-cancer
#17
Muriel Brackstone, David Palma, Alan B Tuck, Leslie Scott, Kylea Potvin, Theodore Vandenberg, Francisco Perera, David D'Souza, Donald Taves, Anat Kornecki, Giulio Muscedere, Ann F Chambers
PURPOSE: To evaluate whether concurrent neoadjuvant radiation added to standard chemotherapy could increase the pathologic complete response (pCR) to treatment for locally advanced breast cancer (LABC). METHODS AND MATERIALS: This prospective phase 2 trial recruited 32 LABC patients from 2009 to 2011. Patients received neoadjuvant every-3-weekly 5-fluorouracil (500 mg/m(2)), epirubicin (100 mg/m(2)), and cyclophosphamide (500 mg/m(2)) for 3 cycles, followed by weekly docetaxel (35 mg/m(2)) for 9 cycles...
June 20, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28869790/evaluating-the-role-of-magnetic-resonance-imaging-post-neoadjuvant-therapy-for-breast-cancer-in-the-neonab-trial
#18
Caitlin Murphy, Violet Mukaro, Robert Tobler, Rebecca Asher, Emma Gibbs, Linda West, Bruno Giuffre, Sally Baron-Hay, Mustafa Khasraw
BACKGROUND: Magnetic Resonance Imaging (MRI) accuracy after neoadjuvant systemic therapy (NST) for breast cancer varies according to hormone receptor (HR), human epidermal growth factor receptor type-2 (HER2) subtype and Ki67 proliferation index. Whether MRI accuracy varies by genomic signatures is unknown. We examined accuracy of MRI in the NEONAB trial (Clinicaltrials.gov #: NCT01830244). METHODS: Patients with stage II-III breast cancer received sequential epirubicin, cyclophosphamide and nab-paclitaxel and trastuzumab if HER2+...
September 4, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28862112/indications-of-the-magnetic-resonance-method-in-breast-pathology
#19
Adina Chiriţă
The high incidence of breast cancer is a known fact. The 5-year survival rate for women with correctly treated breast cancer is 90% around the world, and 50% in Romania, respectively. Correct diagnostic evaluation of the breasts allows for a competent therapeutic management. The primary diagnosis of breast cancer includes clinical examination of the breasts, breast ultrasound and mammography. Magnetic resonance imaging (MRI) examination is not a first line type of investigation, but targeted to selected patient groups...
July 2017: Chirurgia
https://www.readbyqxmd.com/read/28862111/how-can-we-improve-education-of-breast-surgeons-across-europe
#20
Agnieszka Kolacinska
The proposed global curriculum developed by the American Society of Surgical Oncology (SSO) and the European Society of Surgical Oncology (ESSO) and the textbook: provides a state-of- the- art of breast cancer surgery, complements the syllabus and curriculum of the Union Europeenne des Medecins Specialistes (UEMS) examination in breast surgery/ European Board of Surgery Qualification in Breast Surgery (EBSQinBS) administered by ESSO (1) Knowledge and understanding of the principles of breast cancer incidence, aetiology, risk factors, genetics, premalignant and high-risk lesions, pathology, prognostic and predictive factors, risk prediction models, screening, diagnosis and imaging, breast cancer, oncoplastic, reconstructive breast surgery, axillary surgery and future perspective for this, radiation therapy, neoadjuvant and adjuvant systemic treatment- endocrine-, immuno- and chemotherapy, side effects and toxicities of treatment, locoregional recurrence, follow-up, locally advanced breast cancer, metastatic breast cancer, breast cancer in young and elderly patients, survivor issues, lymphedema, palliative care, chroni pain, body image and sexuality, fertility issues, cognitive functions, etc...
July 2017: Chirurgia
keyword
keyword
74676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"